Malignant neoplasm of thyroid
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pasireotide LAR has modest in vivo efficacy and the combination of everolimus and pasireotide LAR achieve greater tumor growth inhibition than each agent alone in TPC-1 xenograft model of thyroid cancer (p = 0.048).
|
30807575 |
2019 |
Malignant neoplasm of thyroid
|
0.100 |
Biomarker
|
disease |
BEFREE |
Anaplastic (8505C, CAL62, SW1736) and papillary (TPC-1) thyroid cancer cell lines were used to dissect the role of miR-650 on malignant hallmarks of transformation.
|
30927143 |
2019 |
Malignant neoplasm of thyroid
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our purpose was to study the combined effect of HDAC inhibitors (HDACi) and ionizing irradiation in thyroid cancer cell lines (Nthy-ori 3-1, WRO, TPC-1 and 8505c).
|
30125607 |
2018 |
Malignant neoplasm of thyroid
|
0.100 |
Biomarker
|
disease |
BEFREE |
Matrine inhibits TPC-1 human thyroid cancer cells via the miR-21/PTEN/Akt pathway.
|
30127885 |
2018 |
Malignant neoplasm of thyroid
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, the biological role of LRP4 in the thyroid cancer in the present study was investigated using the PTC cell lines TPC1, BCPAP and KTC-1.
|
29885843 |
2018 |
Malignant neoplasm of thyroid
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we evaluated the activities of hydroxytyrosol against papillary (TPC-1, FB-2) and follicular (WRO) thyroid cancer cell lines.
|
27592355 |
2017 |
Malignant neoplasm of thyroid
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, a knockdown of galectin-1 in papillary (TPC-1) and anaplastic (8505C) thyroid cancer cell lines was achieved by lentiviral transduction for in vitro experiments.
|
28677745 |
2017 |
Malignant neoplasm of thyroid
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we show that a TRAIL-R2 agonist antibody, lexatumumab, induces apoptosis effectively in some thyroid cancer cell lines (HTh-7, TPC-1 and BCPAP), while more aggressive anaplastic cell lines (8505c and SW1736) show resistance.
|
24603332 |
2014 |
Malignant neoplasm of thyroid
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using 76 papillary thyroid cancer(PTC) tissues and three thyroid cancer cell lines (TPC1, WRO82-1 and XTC), the expression of three genes and DNA methylation were determined by reverse transcription-PCR and methylation-specific PCR.
|
24222120 |
2013 |
Malignant neoplasm of thyroid
|
0.100 |
Biomarker
|
disease |
BEFREE |
In 3 thyroid cancer cell lines (TPC1 from a papillary thyroid cancer, FTC133 from a follicular thyroid cancer, XTC1 from a Hürthle cell carcinoma), small interfering RNA knockdown of RTN4IP1 was used to determine its role in regulating the hallmarks of malignant cell phenotype (cellular proliferation, migration, apoptosis, invasion, tumor spheroid formation, anchorage independent growth).
|
23393170 |
2013 |
Malignant neoplasm of thyroid
|
0.100 |
Biomarker
|
disease |
BEFREE |
Three anaplastic (Hth74, C643, Kat4), one follicular (FTC133), and one papillary (TPC1) TC cell lines were used.
|
22006286 |
2012 |
Malignant neoplasm of thyroid
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We tested the effects of a highly selective B-Raf(V600E) inhibitor, PLX4720, on proliferation, migration, and invasion both in human thyroid cancer cell lines (8505c(B-RafV600E) and TPC-1(RET/PTC-1 and wild-type B-Raf)) and in primary human normal thyroid (NT) follicular cells engineered with or without B-Raf(V600E).
|
21355020 |
2011 |
Malignant neoplasm of thyroid
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Suppression of BRAF pathway in thyroid cancer cell lines (8505C, TPC1 and C643) was achieved using RNA interference (RNAi) for BRAF and the kinase inhibitor, sorafenib.
|
19878585 |
2009 |
Malignant neoplasm of thyroid
|
0.100 |
Biomarker
|
disease |
BEFREE |
We, therefore, investigated the expression of VEGF messenger RNA (mRNA) and production of VEGF protein in cell lines from human primary and metastatic follicular (FTC-133, FTC-236, and FTC-238), papillary (TPC-1), Hürthle cell (XTC-1), and medullary thyroid cancers (MTC-1.1 and MTC-2.2), and in human thyroid tissues (papillary, follicular, medullary, and Hürthle cell cancers, follicular adenomas, and Graves' thyroid tissue) by Northern blot, immunohistochemistry, and enzyme-linked immunosorbent assay (ELISA) studies.
|
9360534 |
1997 |